Posted on 2/21/2017
Spectranetics has announced that the final 12-month results of the Stellarex drug-coated balloon ILLUMENATE pivotal trial have been presented at the Transcatheter Cardiovascular Therapeutics (TCT) conference (29 October–2 November, Washington, DC, USA). The ILLUMENATE trial’s co-principal investigators are Sean Lyden of the Cleveland Clinic, Cleveland, USA, who presented the data, and Prakash Krishnan, Mount Sinai, New York, USA.
Krishnan stated, “First-generation drug-coated balloons forced us to make a choice between top-tier clinical outcomes and the potential safety advantages of a lower drug dose. Based on the compelling Stellarex study results, we no longer need to compromise. In the most challenging patient population studied in a drug-coated balloon investigational device exemption trial ...